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dDepartment of Medicine, University of Calgary, Calgary, Alberta, CanadaAbstractBackground: Results of randomized controlled trials have shown that carotid endarterectomy poses greater perioperative risks to women
than to men. There are limited studies regarding sex differences in carotid angioplasty and stenting.
Objectives: To compare male and female patients undergoing carotid stenting with regard to their intraprocedural complications and 30-day
outcome.
Methods: We reviewed patients who underwent carotid stenting between 1997 and 2007 at our tertiary centre. Distal protection devices were
used in all patients after 1999. Demographics, risk factors, intraprocedural complications, and 30-day outcomes were compared between
female and male patients.
Results: Among 243 patients who underwent 255 procedures, 67 were women (27.6%). The mean (SD) age of the female patients was 72.2
 8.4 years and that of the male patients was 72.0  9.6 years (P ¼ .83). The majority of patients had symptomatic carotid artery disease;
11 women (16.4%) and 30 men (16.0%) were asymptomatic. The following intraprocedural complications were noticed in female vs male
patients: asymptomatic carotid and/or iliac dissections 7.5% vs 0% (P ¼ .001), minor stroke 0% vs 1.1% (P ¼ 1.00), major stroke 0% vs 0.5%
(P ¼ 1.00), and cardiac dysrhythmias 3% vs 2.7% (P ¼ 1.00). At 30 days, the outcomes in women vs men were as follows: mortality 3.0% vs
3.2% (P ¼ 1.00), major stroke 3.0% vs 2.1 % (P ¼ .66), and minor stroke 3.0% vs 3.2% (P ¼ 1.00).
Conclusion: Although minor asymptomatic intraprocedural dissections were more common in women, we did not find any impact of sex on
the 30-day outcome. We concluded that carotid stenting can be performed as safely in women as in men.Re´sume´Contexte : Des essais cliniques controˆle´s avec re´partition ale´atoire ont re´ve´le´ que l’endarte´riectomie carotidienne repre´sente un risque
pe´riope´ratoire plus grand pour les femmes que pour les hommes. Il existe peu d’e´tudes concernant les diffe´rences entre les sexes pour ce qui
est de l’angioplastie carotidienne et de l’implantation d’endoprothe`ses vasculaires.
Objectifs : Comparer les complications en cours d’intervention et les re´sultats observe´s 30 jours apre`s l’intervention dans le cas d’hommes et
de femmes ayant subi l’implantation d’une endoprothe`se carotidienne.
Me´thodes : Nous avons revu les dossiers de patients ayant subi l’implantation d’une endoprothe`se carotidienne entre 1997 et 2007 au sein de
notre centre de soins tertiaires. Apre`s 1999, des appareils de protection distale ont e´te´ utilise´s syste´matiquement chez tous les patients. Les
donne´es de´mographiques, les facteurs de risque, les complications en cours d’intervention et les re´sultats 30 jours apre`s l’intervention ont fait
l’objet d’une comparaison selon le sexe.
Re´sultats : En tout, 243 patients ont subi 255 interventions; 67 e´taient des femmes (27,6 %). L’aˆge moyen de ces dernie`res e´tait de 72,2 ans
( 8,4 ans), tandis que chez les hommes, l’aˆge moyen e´tait de 72,0 ( 9,6 ans) (P ¼ 0,83). La majorite´ des patients pre´sentaient une affection
carotidienne symptomatique; 11 femmes (16,4 %) et 30 hommes (16,0 %) e´taient asymptomatiques. Voici les complications en
cours d’intervention enregistre´es pour les femmes et les hommes : dissection carotidienne ou iliaque asymptomatique, 7,5 % contre 0 %Disclosures: The authors have no conflicts of interest to disclose.
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S19Carotid angioplasty and stenting in women / Canadian Association of Radiologists Journal 63 (2012) S18eS22(P ¼ 0,001), accident ce´re´bral vasculaire mineur, 0 % contre 1,1 % (P ¼ 1,00), accident ce´re´bral vasculaire grave, 0 % contre 0,5 % (P ¼
1,00), et arythmie cardiaque, 3 % contre 2,7 % (P ¼ 1,00). Voici les re´sultats enregistre´s 30 jours apre`s l’intervention pour les femmes et pour
les hommes : de´ce`s, 3,0 % contre 3,2 % (P ¼ 1,00), accident ce´re´bral vasculaire grave, 3,0 % contre 2,1 % (P ¼ 0,66), accident ce´re´bral
vasculaire mineur, 3,0 % contre 3,2 % (P ¼ 1,00).
Conclusion : Malgre´ que les cas de dissection asymptomatique en cours d’intervention aient e´te´ plus nombreux chez les femmes que chez les
hommes, les re´sultats observe´s apre`s 30 jours ne diffe`rent pas selon le sexe. Nous sommes arrive´s a` la conclusion que l’implantation
d’endoprothe`ses carotidiennes ne pre´sente pas de risques plus e´leve´s chez les femmes que chez les hommes.
 2012 Canadian Association of Radiologists. All rights reserved.
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Carotid endarterectomy poses greater perioperative risks
to women than to men. The European Carotid Surgery Trial
found a significantly increased periprocedural risk for
women (10.4%) compared with men (5.8%) who underwent
carotid endarterectomy [1]. The North American Symptom-
atic Carotid Endarterectomy Trial (NASCET) demonstrated
a greater perioperative risk to women (7.6%) than to men
(5.9%) after carotid endarterectomy [2]. In parallel, the
ACAS and ACST showed no clinical benefit of carotid
endarterectomy among asymptomatic women [3,4].
Carotid angioplasty and stenting might be an effective
alternative to carotid endarterectomy, especially in high-risk
patients, because carotid stenting may avoid anesthetic risk
and surgical risk of cranial nerve palsy [5]. In patients with
previous neck surgery or radiotherapy, carotid stenting is the
preferred interventional option [6].
Three European trials (the International Carotid Stenting
Study [ICSS], the Stent-Supported Percutaneous Angioplasty
of the Carotid Artery vs Endarterectomy [SPACE] study, and
the Endarterectomy vs Stenting in Patients with Symptomatic
Severe Carotid Stenosis [EVA -3S]) that involve symptomatic
carotid stenosis patients showed that carotid endarterectomy
had a lower periprocedural complication rate [7e9]. In
subgroup analysis of the SPACE study [8], the risk of ipsi-
lateral stroke or death increased significantly with age in the
carotid stenting group (P¼.001). The rate of primary outcome
events was 2$7% in patients who were 68 years old or younger
and 10$8% in older patients [10].
The preliminary result from Carotid Revascularisation
Endarterectomy vs Stenting (CREST), the largest prospec-
tive randomized trial, comparing carotid endarterectomy
(CEA) and carotid angioplasty and stenting (CAS) from 117
U.S. and Canadian centres, shows a nonsignificant differ-
ence in the composite primary end point of any stroke,
myocardial infarction, or death during the periprocedural
period or ipsilateral stroke on 4-year follow-up; stenting
was associated with a 7.2% rate of these events vs 6.8%
with surgery. Women formed 35% of the patient population
in this trial, and there was no evidence of a differential
effect of one procedure or the other by sex [11]. We sought
to study, at our institution. carotid stenting patients for sex
differences.Methods
This is a retrospective cohort study of patients who
underwent carotid angioplasty and stenting at a tertiary care
centre between 1997 and 2007. The qualifying event,
demographic and stroke risk factors, and treatment history,
including the use of antiplatelets, statins, and anti coagulants,
were obtained through chart review. The qualifying events
were categorized as symptomatic and asymptomatic by the
treating physicians. Transient ischemic attack (defined as any
focal neurologic deficit caused by cerebral ischemia that
resolved within 24 hours from onset), a retinal event (defined
as transient or permanent monocular vision loss ipsilateral to
carotid stenosis), and ipsilateral ischemic stroke were
considered symptomatic events. All other stented patients
were considered asymptomatic.
The cause and degree of stenosis and the stent type were
recorded. The degree of stenosis preprocedure was deter-
mined primarily by the computed tomographic (CT) angi-
ography but also by duplex ultrasound or magnetic resonance
angiography of the neck vessels. The degree of stenosis was
defined by using the NASCET criteria applied to CT source
images, as well as reconstructed sagittal and coronal tomo-
graphic images from CT, and categorized into moderate
(50%e70% stenosis), severe (more than 70%), and near
occlusion (more than 95% stenosis with collapsed distal
internal carotid artery [ICA]). The procedures were per-
formed by 4 experienced neurointerventionalists. The deci-
sion regarding stenting vs endarterectomy was taken by the
treating team (neurointerventionalist, neurosurgeon, and
stroke neurologist) and after discussion with the patient.
Patients who had major medical comorbidities and high-risk
anatomic patterns of carotid vasculature (eg, surgically
inaccessible stenosis, inadequate collateral circulation)
underwent stenting. Informed consent was obtained from all
patients.
Carotid stenting was performed with the patient under
conscious local anaesthesia. Patients were premedicated with
aspirin and clopidogrel. An intravenous heparin bolus was
given to patients before the procedure, and a femoral access
route was used. Distal protection devices were used in all
cases from 1999 onward, and the device most commonly
used was the FilterWire EZ Embolic Protection System
(Boston Scientific, Natick, MA). All patients underwent
Table 1
Risk factors and medications
Risk factor and medications
Female patients
(n ¼ 67) (%)
Male patients
(n ¼ 188) (%) P value
Age mean (SD) 72.2  8.4 y 72.0  9.6 y .83
Age >80 y 13 (19.4) 48 (25.5) .40
Coronary artery disease 28 (41.8) 93 (49.5) .32
Myocardial infarction 17 (25.4) 64 (34.0) .22
Chronic obstructive
pulmonary disease
16 (23.9) 28 (14.9) .13
Diabetes mellitus 18 (26.9) 51 (27.1) 1.00
Peripheral vascular disease 7 (10.4) 36 (19.1) .13
Hypertension 60 (89.6) 153 (81.4) .18
Smoking 22 (32.8) 54 (28.7) .54
Aspirin 58 (86.6) 183 (97.3) <.01
Clopidogrel 60 (89.6) 177 (94.1) .26
Statin 45 (67.2) 123 (65.4) .88
Warfarin 14 (20.9) 29 (15.4) .34
High-risk category 4 (6.0) 20 (10.6) .34
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Carotid WallStent (Boston Scientific), Acculink (Guidant,
Santa Clara, CA), Precise (Cordis, Miami, FL), AVE (AVE
Ireland), and Protege (ev3 Inc, Plymouth, MN) stents were
used. Patients were admitted to a close observation stroke
unit for the first 24 hours after the procedure. Clopidogrel
was discontinued after 2 months, and it was recommended
that aspirin be continued lifelong for all patients. A high-risk
patient was defined as a patient who had any of the
following: significant cardiac disease, severe pulmonary
disease, contralateral carotid occlusion, previous neck
surgery or radiation, age 80 years or older, or recurrent
carotid stenosis after carotid endarterectomy. Significant
cardiac disease was defined by a history of coronary angio-
plasty or cardiac bypass surgery. Severe pulmonary disease
was defined as any pulmonary disease that required home
oxygen therapy.
The primary outcome was stroke or death at 30 days.
Stroke was defined as a new focal neurologic deficit of
presumed vascular origin that persisted more than 24 hours,
supported by appropriate findings on radiologic imaging.
Stroke was considered major if hospitalization was required
or prolonged. Neurologic death was defined as death related
to a massive stroke or intracerebral hemorrhage. Patients
were followed up in the stroke clinic and were examined by
a stroke neurologist at 30 days. When the 30-day follow-up
data were not available, the vital status of the individual at
that time was sought. Intraprocedural complications were
defined as complications that occurred during the procedure.
The study was approved by the institutional review board.










Time from symptom onset to
carotid stenting
Weeksa 8.1 (13.7) 4.6 (13.5)
No. (%) within 2 wk 14 (20.9) 45 (23.9)
Degree of stenosis
50%e69% 12 (17.9) 28 (14.9)
70% 49 (73.1) 147 (78.2)
Near occlusion 6 (9.0) 13 (19.4)
Cause of stenosis
Atherosclerosis 62 (92.5) 175 (93.1)
Dissection 0 (0) 1 (0.5)
Fibromuscular dysplasia 3 (4.5) 3 (1.6)
Radiation 2 (3.0) 9 (4.8)
Asymptomatic stenosis 11 (16.4) 30 (16.0)
Stent type
Acculink 4 (6.0) 18 (9.6)
Wallstent 42 (62.7) 130 (69.1)
Others 6 (9.0) 18 (9.6)
Not specified 15 (22.4) 22 (11.7)
Use of distal protection device 66 (98.5) 176 (93.6)
aMedian weeks (interquartile range).Data are reported by sex by using standard descriptive
statistics. Continuous variables were expressed as absolute
numbers and percentages. All proportions were assessed by
using the Fisher test. The Wilcoxon rank sum test was used
to compare categorical variables. Statistical significance was
fixed at P < .05, and all tests were 2 sided.
Results
A total of 243 patients underwent 255 carotid stenting
procedures. Their ages ranged from 50e83 years; the mean
(SD) age was 72.0  9.3 years. Sixty-seven were women
(27.6%); 176 men underwent 188 procedures. There were no
significant differences between men and women with regard
to the modifiable stroke risk factors (Table 1). Fewer women
received aspirin before the procedure compared with men,
however, there were several reasons, including allergy to
aspirin, gastrointestinal tract bleed, and the use of warfarin
and ticlopidine. Twelve women (17.9%) and 39 men (20.7%)
participated in clinical trials: CREST [11]/Medtronic AVE
Self-expanding CaRotid Stent System with distal protection
(MAVERIC) [12]. The procedure characteristics are shownin Table 2. There were significantly more asymptomatic
dissections in women: 4 female patients had carotid dissec-
tions, which were small, nonocclusive, and asymptomatic,
and 1 had proximal internal iliac dissection. None of the
male patients had dissections (Table 3). Thirty-day follow-up
data were available for 244 patients (95.7%). There was no
evidence of differential sex effect for 30-day outcomes
(Table 3). Transient neurologic dysfunction was found in 1
patient in the female group and in 4 patients in the male
group. However, the exact mechanism could not be ascer-
tained because investigations, including electroencephalo-
gram and brain and carotid imaging were normal. Sex was









(total ¼ 188) P value
Days of hospital staya 2 (4) 2 (2)
Procedure-related events
Asymptomatic dissection 5 (7.5) 0 (0) .001
Minor stroke 0 (0) 2 (1.1) 1.00
Major stroke 0 (0) 1 (0.5) 1.00
Cardiac dysrhythmia 2 (3.0) 5 (2.7) 1.00
Hemodynamic instability 0 (0) 4 (2.1) .58
Overall 30-day outcomeb
Mortality (any cause) 2 (3.0) 6 (3.2) 1.00
Neurologic death 1 (1.5) 4 (2.1) 1.00
Non-neurologic death 1 (1.5) 2 (1.1) 1.00
Major stroke 2 (3.0) 4 (2.1) .66
Minor stroke 2 (3.0) 6 (3.2) 1.00
Major stroke or death 4 (6.0) 10 (5.3) .76
All stroke and death 6 (9.0) 16 (8.5) 1.00
Transient neurologic deficit 1 (1.5) 4 (2.1) 1.00
Myocardial infarction 0 (0) 2 (1.1) 1.00
Hyperperfusion syndrome 2 (3.0) 1 (0.5) .17
aMedian days (interquartile range).
bOverall 30-day outcome include intraprocedural outcomes.
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Consistent data from NASCET, ACE, and a retrospective
U.S. study have shown that women have higher periproce-
dural complications after carotid endarterectomy compared
with men [2,13]. The putative reason for this is differences in
the anatomy in women, which makes the surgical procedure
more difficult to perform or leads to a higher incidence of
carotid thrombosis [14,15]. The lower magnitude of benefit
observed in women undergoing carotid endarterectomy is in
part because of this higher procedural risk compared with
men, a consistent finding across all of the symptomatic and
asymptomatic randomized trials and reiterated in a system-
atic review of the published literature [16,17]. Results of our
data suggest that this disadvantage for women may be
alleviated by the use of carotid stenting.
Carotid artery stenting and angioplasty is an alternative to
carotid endarterectomy, especially in high surgical and
anatomical risk patients. The ACCULINK for Revasculari-
zation of Carotids in High-risk patients (ARCHeR) trial data
supported the noninferiority of carotid stenting to carotid
endarterectomy in high-risk surgical patients [18]. As per
guidelines of American Heart Association/American Stroke
Association 2006, carotid stenting is a reasonable treatment
option when performed by experienced and skilled operators,
with established periprocedural morbidity and mortality rates
of 4%e6% [19]. At centres with limited carotid endarter-
ectomy experience, carotid stenting is a viable option [20].
Asymptomatic dissections were the most common
procedure-related events in the female cohort in our study.
This could be secondary to 40% smaller internal carotid
diameters in women [21]. Significantly higher coronary
dissections are documented in female patients of coronary
artery disease (CAD) undergoing percutaneous transluminalcoronary angioplasty (PTCA) also, compared with male
patients [22]. Whether dissection leads to endothelial injury
and stenosis in stenting patients during long-term follow-up
is not known. Female sex was one of the predictors of
restenosis after carotid stenting in 1 report, but these reste-
noses were asymptomatic [23].
In our study, the primary end point, stroke, and 30-day
all-cause mortality were not different between women
(9.0%) and men (8.5%). The benefit of carotid intervention
compared with medical therapy is largely dependent upon
the periprocedural risks of the carotid stent procedure [24].
In the SPACE trial, 7.74% of women compared with 6.50%
of men had ipsilateral stroke or death at 30 days from the
time of randomization, although there was no statistically
significant difference [8]. Similar results have been reported
from the lead-in phase of CREST, the Carotid Reva-
scularization Using Endarterectomy or Stenting Systems
(CARESS) study, and several registries [10,25e28].
However, the major European randomized controlled trials
have not specifically reported on the impact of sex on
carotid stenting outcomes [29e31]; the CREST study
specifically assessed for a sex-by-treatment interaction and
found no evidence of a differential outcome on the primary
composite outcome [11].
We did not have technical details, such as vessel calibre or
anthropomorphic measures to assess the biologic hypothesis
that differences in vessel size are associated with differences
in morbidity for carotid intervention. In addition, our study
was retrospective and subject to inherent biases typical of
such studies. However, our data are consistent with existing
literature; we did not find any impact of sex on 30-day
outcome after carotid stenting.
Conclusion
Carotid stenting can be performed as safely in women as
in men. It is essential that clinical trials and registries report
sex-specific outcomes for more robust evidence regarding the
absence of effect of sex on outcomes after carotid
intervention.
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